The cost of diabetes chronic complications among Iranian people with type 2 diabetes mellitus

Journal of Diabetes & Metabolic Disorders

Maryam Ebadi³  Abbas Keshtkar⁵  Rokhsareh Aghili⁴  Mohamad Ebrahim Khamseh⁴  Farid Abedin Dorkoosh²  Mohammad Abdollahi¹  Abbas Kebriaeezadeh²  Ali Akbari Sari⁶  Alireza Esteghamati³  Amir Farshchi² 

[1] Department of Toxicology and Pharmacology, School of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of medical Sciences, Tehran, Iran;Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran;Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran;Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran;Osteoporosis Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran;Department of Health Management and Economics, Tehran University of Medical Sciences, Tehran, Iran

关键词: QALY;    Productivity;    HbA1c;    Complication;    Type 2 diabetes mellitus;    Cost;   

Others  :  804688
DOI  :  10.1186/2251-6581-13-42

 received in 2013-12-11, accepted in 2014-02-22,  发布年份 2014

【 摘 要 】

Background

To evaluate the cost of diabetes related micro- and macrovascular complications in Iranian people with type 2 diabetes mellitus.

Methods

In routine clinical practice, people with type 2 diabetes mellitus were assessed for 10 years at a diabetes care center. The type of medications and clinical data were extracted from patients’ documents. Mortality rate and the incidence of micro- and macrovascular complications recorded in patients’ documents were analyzed. Cost analysis was comprised of 1) para clinic costs as well as laboratory, medications, clinical visits and nonmedical costs 2) inpatient costs as well as hospital admission costs, disability, and mortality costs.

Results

From 1562 people with type 2 diabetes mellitus, a total of 1000 patients with mean duration disease of 11.2 years, who had completed information in their documents, were studied. All people were free from complications at baseline. Mean cumulative incidence of diabetes-related complications over 10 years were 10.9 ± 3.5%, 8.0 ± 3.1%, 4.6 ± 1.7%, 9.1 ± 3.6% and 2.3 ± 0.9% for peripheral neuropathy and diabetic foot ulcer, nephropathy, ophthalmic complications, cardiovascular disease and death, respectively. People with better glycemic control had less complication and also related expenditures. Average para clinic cost per patient was 393.6 ± 47.8 and average inpatient cost per patient was 1520.7 ± 104.5 USD.

Conclusions

Our findings demonstrate considerable incidence of diabetes chronic complications and also high health care expenditure for related complications among our patients. As the number of people with diabetes continues to rise, early detection of the disease and implementation of timely and appropriate therapeutic strategies could decrease the burden of diabetes chronic complications and also huge related expenditures.

【 授权许可】

   
2014 Farshchi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaedini F, Safaie A, Forouzanfar M, Gregg EW: Prevalence of Diabetes and Impaired Fasting Glucose in the Adult Population of Iran National Survey of Risk Factors for Non-Communicable Diseases of Iran. Diabetes Care 2008, 31(1):96-98.
• [2]Aghili R, Khamseh ME, Malek M, Yarahmadi S, Farshchi A: Structured self monitoring of blood glucose in Iranian people with type 2 diabetes; A cost consequence analysis. DARU Journal of Pharmaceutical Sciences 2012, 20(1):1-6. BioMed Central Full Text
• [3]Boushehri E, Khamseh ME, Farshchi A, Aghili R, Malek M, Ebrahim Valojerdi A: Effects of morning report case presentation on length of stay and hospitalisation costs. Medical education 2013, 47(7):711-716.
• [4]The Global Burden. http://www.idf.org/sites/default/files/attachments/5E_IDFAtlasPoster_2012_EN.pdf?utm_medium=email&utm_campaign=IDF%20Diabetes%20Atlas%202012%20Update&utm_content=IDF%20Diabetes%20Atlas%202012%20Update+Preview+CID_720a5262162f1f585ba9fc8ca39fef30&utm_source=campaignmonitor&utm_term=English webcite
• [5]Farshchi A, Nikfar S, Seyedifar M, Abdollahi M: Effect of Chromium on Glucose and Lipid Profiles in Patients with Type 2 Diabetes; A Meta-analysis Review of Randomized Trials. Journal of Pharmacy & Pharmaceutical Sciences 2013, 16(1):99-114.
• [6]Farshchi A, Nikfar S, Abdollahi M: Concerns on the use of chromium in type 2 diabetes mellitus; needs to conduct major meta-analysis. Int J Pharmacol 2012, 8(6):470-472.
• [7]American Diabetes Association: Standards of medical care in diabetes-2013. Diabetes Care 2013, 36(Suppl 1):S11-S66.
• [8]Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj 2000, 321(7258):405-412.
• [9]Sobel BE, Schneider DJ: Cardiovascular complications in diabetes mellitus. Current Opinion in Pharmacology 2005, 5(2):143-148.
• [10]Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999, 100(10):1134-1146.
• [11]Azizi F: Diabetes care and prevention in Iran. Diabetes Voice 2005, 50(4):15-17.
• [12]Zhou H, Isaman DJ, Messinger S, Brown MB, Klein R, Brandle M, Herman WH: A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 2005, 28(12):2856-2863.
• [13]Oglesby AK, Secnik K, Barron J, Al-Zakwani I, Lage MJ: The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Effectiveness and Resource Allocation 2006, 4(1):1. BioMed Central Full Text
• [14]Menzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, Neumann PJ: Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. Journal of Managed Care Pharmacy 2010, 16(4):264.
• [15]Zhang P, Zhang X, Brown JB, Vistisen D, Sicree RA, Shaw J, Nichols GA: Economic impact of Diabetes. Diabetes Atlas, IDF 2010, 4:1-28.
• [16]Goeree R, Lim ME, Hopkins R, Blackhouse G, Tarride J-E, Xie F, O'Reilly D: Prevalence, total and excess costs of diabetes and related complications in Ontario. Canada. Canadian Journal of Diabetes 2009, 33(1):35-45.
• [17]Javanbakht M, Baradaran HR, Mashayekhi A, Haghdoost AA, Khamseh ME, Kharazmi E, Sadeghi A: Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PloS one 2011, 6(10):e26864.
• [18]Esteghamati A, Jamali A, Khalilzadeh O, Noshad S, Khalili M, Zandieh A, Morteza A, Nakhjavani M: Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetecl non-alcoholic fatty liver disease by ultrasound. Diabetol Metab Syndr 2010, 2(1):65-71. BioMed Central Full Text
• [19]Lentjes E, Harff G, Backer E: Evaluation of the Hitachi 704 automatic analyzer. Clinical chemistry 1987, 33(11):2089-2092.
• [20]Central Bank of Iranhttp://www.cbi.ir/exrates/rates_fa.aspx webcite
• [21]Morgan C, Currie C, Stott N, Smithers M, Butler C, Peters J: The prevalence of multiple diabetes related complications. Diabetic medicine 2000, 17(2):146-151.
• [22]Juel K, Christensen K: Are men seeking medical advice too late? Contacts to general practitioners and hospital admissions in Denmark 2005. Journal of public health 2008, 30(1):111-113.
• [23]Malek M, Khamseh ME, Rokhsareh A, Laily N, Hamid R: Medical management of diabetic retinopathy: an overview. Archives of Iranian medicine 2012, 15(10):635.
• [24]Degli Esposti L, Saragoni S, Buda S, Sturani A, Degli Esposti E: Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases. Clinico Economics and outcomes research: CEOR 2013, 5:193.
• [25]Esteghamati A, Khalilzadeh O, Anvari M, Meysamie A, Abbasi M, Forouzanfar M, Alaeddini F: The economic costs of diabetes: a population-based study in Tehran, Iran. Diabetologia 2009, 52(8):1520-1527.
• [26]Bertoni AG, Krop JS, Anderson GF, Brancati FL: Diabetes-related morbidity and mortality in a national sample of US elders. Diabetes Care 2002, 25(3):471-475.
• [27]Khamseh ME, Kazemikho N, Aghili R, Forough B, Lajevardi M, Dabaghian FH, Goushegir A, Malek M: Diabetic distal symmetric polyneuropathy: effect of low-intensity laser therapy. Lasers in medical science 2011, 26(6):831-835.
• [28]Aghili R, Khamseh ME, Baradaran HR, Aghili SM, Malek M: Diabetic distal symmetric polyneuropathy: Role of physical examination in screening. Koomesh 2013, 14(3):327-334.
• [29]Abbasian M, Delvarian-Zadeh M: Evaluation of diabetes complications among the diabetic patients visiting the Shahroud diabetic. Knowledge & Health Journal 2008, 10(4):16-20.
• [30]Rate RG, Knowler WC, Morse HG, Bonnell MD, McVey J, Chervenak CL, Smith MG, Pavanich G: Diabetes mellitus in Hopi and Navajo Indians: prevalence of microvascular complications. Diabetes 1983, 32(10):894-899.
• [31]Börü U, Alp R, Sargin H, Koçer A, Sargin M, Lüleci A, Yayla A: Prevalence of peripheral neuropathy in type 2 diabetic patients attending a diabetes center in Turkey. Endocrine journal 2004, 51(6):563.
• [32]Janghorbani M, Rezvanian H, Kachooei A, Ghorbani A, Chitsaz A, Izadi F, Amini M: Peripheral neuropathy in type 2 diabetes mellitus in Isfahan, Iran: prevalence and risk factors. Acta neurologica scandinavica 2006, 114(6):384-391.
• [33]Turner R, Holman R, Stratton I, Cull C, Matthews D, Manley S, Frighi V, Wright D, Neil A, Kohner E: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352(9131):854-865.
• [34]Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, Wagner EH: Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999, 22(3):382-387.
• [35]Cruickshanks K, Ritter L, Klein R, Moss S: The association of microalbuminuria with diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 1993, 100(6):862.
• [36]Remuzzi G, Schieppati A, Ruggenenti P: Nephropathy in patients with type 2 diabetes. New England Journal of Medicine 2002, 346(15):1145-1151.
• [37]Amini M, Safaei H, Aminorroaya A: The incidence of microalbuminuria and its associated risk factors in type 2 diabetic patients in Isfahan, Iran. The review of diabetic studies: RDS 2007, 4(4):242.
• [38]Moradi S, Baradaran H: Prevalence of retinopathy and microalbuminuria in people with type 2 diabetes at Tehran Institute of Endocrine and Metabolism, Iran. Diabet Med 2006, 23(Suppl 4):181.
• [39]Shakiba Mehrdad AAM, Orafa A: A Study of the Prevalence of Micro & Macro Albuminuria in Diabetic Patients Referring to the Diabetic Centre in Yazd. Journal of Shahid Sadoughi University of Medical Sciences and Health Services 2003, 10(4):20-24.
• [40]Khan K, Khan M, Haque M: Correlation between Microalbuminuria with Complexity of Coronary Artery Disease in Diabetic Patients. Mymensingh medical journal: MMJ 2013, 22(2):353-357.
• [41]Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D, Fortuny J: Burden of illness of diabetic macular edema: literature review. Current Medical Research & Opinion 2010, 26(7):1587-1597.
• [42]Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl M-C, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C: The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature genetics 2000, 26(1):76-80.
• [43]Saaddine JB, Honeycutt AA, Narayan K, Zhang X, Klein R, Boyle JP: Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. Archives of Ophthalmology 2008, 126(12):1740.
• [44]Melmed S, Polonsky KS, Larsen PR, Kronenberg HM: Williams Textbook of Endocrinology. 12th edition. Philadelphia, U.S: Elsevier Health Sciences; 2011.
• [45]Nathan DM, Cleary PA, Backlund J, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353(25):2643-2653.
• [46]Grundy SM, Howard B, Smith S, Eckel R, Redberg R, Bonow RO: Diabetes and cardiovascular disease executive summary conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002, 105(18):2231-2239.
• [47]American Diabetes Association: Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013, 36(4):1033-1046.
• [48]World Bank organizationhttp://data.worldbank.org/indicator/SH.XPD.PCAP webcite
• [49]Khalili D, Hadaegh F, Tohidi M, Fahimfar N, Eskandari F, Azizi F: Lucose intolerance as a risk factor for cardiovascular outcomes: Tehran Lipid and Glucose Study (TLGS). Tehran University Medical Journal 2010, 67(11):778-786.
• [50]Klein R: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995, 18(2):258-268.
• [51]Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Predictors of stroke in middle-aged patients with non–insulin-dependent diabetes. Stroke 1996, 27(1):63-68.
• [52]Jagger C, Goyder E, Clarke M, Brouard N, Arthur A: Active life expectancy in people with and without diabetes. Journal of public health 2003, 25(1):42-46.
• [53]Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P: Productivity and medical costs of diabetes in a large employer population. Diabetes Care 2002, 25(1):23-29.
• [54]Tunceli K, Bradley CJ, Nerenz D, Williams LK, Pladevall M, Lafata JE: The impact of diabetes on employment and work productivity. Diabetes Care 2005, 28(11):2662-2667.
• [55]Fauci A, Braunwald E, Kasper D, Hauser S, Longo D, Jameson G, Loscalzo J: Diabetes mellitus. In Harrison's Principles of internal medicine. 17th edition. New York: Mc Graw Hill; 2008:2968-3003.
• [56]Soleymani F, Farshchi A, Haerizadeh M: Prescription pattern study of type 2 diabetes mellitus in Iran. Value in Health 2011, 14(7):A484-A484.
• [57]Farshchi A, Jaberidoost M, Abdollahiasl A, Abdollahi M: Efficacies of regulatory policies to control massive use of diphenoxylate. Int J Pharm 2012, 8:459-462.